The immune system is constantly on the alert for cells that have sustained DNA damage. When a cell divides its DNA molecules are, to varying degrees, usually damaged. Yet researchers…
Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…
One in every eight women will be diagnosed with breast cancer within their lifetime. Yet despite the prevalence, there are still many myths about this diagnosis. For example, some people…
Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…
A Phase 1/2 clinical trial sought to evaluate the potential of vepdegestrant as a therapeutic option for heavily pretreated individuals with estrogen receptor-positive (ER+) and HER2 negative (HER2-) advanced…
The FDA has granted IDEAYA Biosciences fast track status for IDE161 as a treatment for HR+, Her2- breast cancer. The therapy is a selective inhibitor of ADP ribose glycohydrolase…
Patient Worthy is expanding its platform for sharing patient stories through the production of short-form videos featuring rare disease patients. Recently, we sat down with Margaret, who lives with metastatic…
We are excited to announce that Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back in action with a new episode. Colby and…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
When Al and Terry Rezsel were married, they took their vows seriously: in sickness and in health. So when Terry was diagnosed with breast cancer in 2010, after 10 years…
In the past, there have been specific genetic mutations associated with breast cancer: most often the BRCA1 and BRCA2 genes. Altogether, there are 15 genes associated with a moderate-to-high…
In 2018, Libby Porter welcomed her first child into the world. Her family was thrilled, especially her father John, who was so excited to have a granddaughter. But things…
An antidepressant drug that was approved by the FDA in 1959 is being put to new and promising use to fight hard-to-treat breast cancers. The antidepressant, imipramine, was approved to…
Before you read on, make sure to check out: Part 1: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton talk about the importance of Alzheimer's disease awareness. …
Before you read on, don't forget to take a look at Part 1 of our interview. In Part 1, Savanah discussed what metastatic breast cancer (MBC) is, her diagnostic journey, and treatment…
October is Breast Cancer Awareness Month. This month is dedicated to raising awareness about the impact of breast cancer, raising funds for research, supporting those with breast cancer, and advocating…
According to an article recently published in Targeted Oncology, the FDA approved olaparib (Lynparza), a product of AstraZeneca Pharmaceuticals, in March of this year. Lynparaza will be used as adjuvant…
In the Phase 3 KEYNOTE-522 clinical trial, researchers found that pembrolizumab was effective in treating patients with triple-negative breast cancer (TNBC). According to Medical XPress, researchers wanted to determine whether…
A recent study has evaluated the incidence of thromboembolic events (TEE) in patients diagnosed with advanced HR-positive, HER2-negative breast cancer. Specifically, researchers were concerned that treatment with cyclin dependent kinase…
AstraZeneca and Daiichi-Sankyo are participating in a global collaboration to develop Enhertu (trastuzumab deruxtecan) for the treatment of HER2-low metastatic breast cancer (cancer that has spread). Enhertu is an ADC…
Is there a relationship between increased sun exposure and breast cancer risk? At first glance, you might think, “Sure. Sun exposure probably increases the risk.” However, according to an article…
Novartis has recently announced the results of their Phase II BYLieve trial, which is investigating Piqray® (alpelisib) as a treatment for hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-)…
According to an article posted by Morningstar, IMV Inc. has dosed the first patient in its Phase 1b trial of maveropepimut-S (MVP-S), which will investigate safety in patients with hormone…
IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…
In the past, caffeine has been somewhat of a complex or even controversial topic. While some research shares that it is bad for health, others laud caffeine’s ability to enhance…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
